Rigel Pharmaceuticals (RIGL) came out with quarterly earnings of $0.63 per share, beating the Zacks Consensus Estimate of $0.14 per share. This compares to loss of $0.50 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 350%. A quarter ago, it was expected that this drug developer would post earnings of $0.55 per share when it actually produced earnings of $0.80, delivering a surprise of 45.45%.Over the last four quarters, the c ...

Q1 2025 Financial Results Presentation May 6, 2025 1 Forward Looking Statements This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1955 ("PSLRA") relating to, among other things, continued development and expansion of our business, projected financial performance including sales and revenue growth, potential results of our Phase 1b study of R289 in R/R lower-risk MDS, future Phase 2 studies of olutasidenib in recurrent glioma, potentia ...

Rigel Pharmaceuticals (RIGL) Q1 2025 Earnings Call May 06, 2025 04:30 PM ET Speaker0 Greetings, and welcome to Rigel Pharmaceuticals Financial Conference Call for the First Quarter twenty twenty As a reminder, this conference is being recorded. It is now my pleasure to introduce our first speaker, Ray Furey, Rigel's Executive Vice President, General Counsel and Corporate Secretary. Thank you, Mr. Furey. You may begin. Speaker1 Welcome to our first quarter twenty twenty five financial results and business up ...

Exhibit 99.1 Rigel Reports First Quarter 2025 Financial Results and Provides Business Update SOUTH SAN FRANCISCO, Calif., May 6, 2025 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL), a commercial stage biotechnology company focused on hematologic disorders and cancer, today reported financial results for the first quarter ended March 31, 2025, including sales of TAVALISSE (fostamatinib disodium hexahydrate), GAVRETO (pralsetinib) and REZLIDHIA (olutasidenib), and recent business progress. · Net p ...

WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED MARCH 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Commission File Number 0-29889 Rigel Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 94-3248524 (St ...

Contact for Investors & Media: Investors: Rigel Pharmaceuticals, Inc. 650.624.1232 [email protected] Media: David Rosen Argot Partners Phone: 646.461.6387 SOURCE Rigel Pharmaceuticals, Inc. SOUTH SAN FRANCISCO, Calif., April 29, 2025 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that it will report its first quarter 2025 financial results after market close on Tuesday, May 6, 2025. Rigel senior management will follow the announcement with a live conference call and webcast at 4: ...

Rigel Pharmaceuticals (RIGL) could be a solid choice for investors given its recent upgrade to a Zacks Rank #2 (Buy). This upgrade primarily reflects an upward trend in earnings estimates, which is one of the most powerful forces impacting stock prices.The Zacks rating relies solely on a company's changing earnings picture. It tracks EPS estimates for the current and following years from the sell-side analysts covering the stock through a consensus measure -- the Zacks Consensus Estimate.The power of a chan ...

Scientist and trader of biotech stock. Focus on trading around events such as trial results and NDA/BLA approvals. Also covering companies in industries regulated by the FDA. Articles present my opinion on stocks, but don't constitute investment advice.Analyst’s Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not re ...

Core Insights - Rigel Pharmaceuticals has reached a settlement agreement with Annora Pharma and its affiliates regarding patent litigation over TAVALISSE, allowing Annora to potentially market a generic version by Q2 2032 or earlier under certain conditions [1][2] - The settlement highlights the strength of Rigel's intellectual property related to TAVALISSE, which is an innovative treatment for immune thrombocytopenia (ITP) [2] - Rigel remains focused on advancing its portfolio of therapies aimed at improving the lives of patients with hematological disorders and cancer [2][6] Company Overview - Rigel Pharmaceuticals, Inc. is a biotechnology company founded in 1996, based in South San Francisco, California, dedicated to developing novel therapies for hematologic disorders and cancer [6] - TAVALISSE (fostamatinib disodium hexahydrate) is indicated for treating thrombocytopenia in adult patients with chronic ITP who have not responded adequately to previous treatments [4] Industry Context - Immune thrombocytopenia (ITP) is a condition where the immune system attacks and destroys the body's blood platelets, leading to symptoms such as excessive bruising and bleeding [3] - Current treatment options for ITP include steroids, platelet production boosters, and splenectomy, but there is a significant medical need for additional therapies as not all patients respond to existing treatments [3]

Core Insights - Rigel Pharmaceuticals has appointed Dr. Mark W. Frohlich to its Board of Directors, bringing over 25 years of experience in developing cellular immunotherapies for cancer treatment [1][2] - Dr. Frohlich's expertise includes clinical drug development, translational research, and portfolio strategy, which will support Rigel's hematology and oncology development pipeline [2][4] - He has previously held significant roles in various biotechnology companies, including as CEO of Indapta Therapeutics and leading portfolio strategy at Juno Therapeutics [2][3] Company Overview - Rigel Pharmaceuticals, Inc. is a biotechnology company focused on discovering and developing novel therapies for hematologic disorders and cancer [4] - The company was founded in 1996 and is based in South San Francisco, California [4] - Rigel aims to improve the lives of patients through its marketed products and pipeline of potential products [4]